Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

(Reuters) -German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent dispute related to mRNA-based COVID-19 vaccines, CureVac said. As ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

CureVac – a German pharmaceutical company – settled a long-running patent dispute with rival BioNTech and Pfizer in the US on ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...

For CureVac’s co-founder, the biologist Ingmar Hoerr, the company’s Covid-19 vaccine trial is the culmination of a quarter-century’s worth of work with RNA, a molecule that helps turn DNA ...

CureVac had some advantages over the other mRNA vaccines, such as keeping stable for months in a refrigerator. What’s more, compared with its competitors, CureVac’s vaccine used fewer mRNA ...

CureVac's experimental COVID-19 vaccine failed in a pivotal clinical study, the biotech said Wednesday. It's the first late-stage study to flop, with CureVac's vaccine showing 47% effectiveness.

The complicated legal wrangling has been brought to a close after CureVac and BioNTech settled their mRNA patent litigation ...